Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - BIO-PATH HOLDINGS INC | tv485337_ex99-1.htm |
| EX-3.1 - EXHIBIT 3.1 - BIO-PATH HOLDINGS INC | tv485337_ex3-1.htm |
| 8-K - FORM 8-K - BIO-PATH HOLDINGS INC | tv485337_8k.htm |
Exhibit 99.2
Bio-Path Holdings to Present at the BIO CEO & Investor Conference
HOUSTON—February 5, 2018 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming BIO CEO & Investor Conference on Monday, February 12, 2018 at 2:45 p.m. ET in New York.
A live webcast of the presentation can be accessed under “Presentations and Publications” in the Media section of the Company’s website at www.biopathholdings.com.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company’s website at http://www.biopathholdings.com.
# # #
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369